AbbVie – Multiple Myeloma

Access Program Information

This is an expanded access program (EAP) for eligible participants. This program is designed
to provide access to Venetoclax prior to approval by the local regulatory agency.
Availability will depend on territory eligibility. Participating sites will be added as they
apply for and are approved for the EAP. A medical doctor must decide whether the potential
benefit outweighs the risk of receiving an investigational therapy based on the individual
patient’s medical history and program eligibility criteria.

Rare Disease: